RSSDI

Yearbook of

Diabetes

2017

RSSDI
Yearbook of
Diabetes
2017

Editor-in-Chief

Sujoy Ghosh DM FRCP (Lond, Glasg, Edin) FACE

Associate Professor
Department of Endocrinology
Institute of Post Graduate Medical Education and Research
Kolkata, West Bengal, India





The Health Sciences Publisher

New Delhi | London | Panama

Jaypee Brothers Medical Publishers (P) Ltd

Headquarters

Jaypee Brothers Medical Publishers (P) Ltd
4838/24, Ansari Road, Daryaganj
New Delhi 110 002, India
Phone: +91-11-43574357
Fax: +91-11-43574314
Email: jaypee@jaypeebrothers.com

Overseas Offices

J.P. Medical Ltd
83 Victoria Street, London
SW1H 0HW (UK)
Phone: +44 20 3170 8910
Fax: +44 (0)20 3008 6180
Email: info@jpmedpub.com

Jaypee-Highlights Medical Publishers Inc
City of Knowledge, Bld. 237, Clayton
Panama City, Panama
Phone: +1 507-301-0496
Fax: +1 507-301-0499
Email: cservice@jphmedical.com

Jaypee Brothers Medical Publishers (P) Ltd
17/1-B Babar Road, Block-B, Shaymali
Mohammadpur, Dhaka-1207
Bangladesh
Mobile: +08801912003485
Email: jaypeedhaka@gmail.com

Jaypee Brothers Medical Publishers (P) Ltd
Bhotahity, Kathmandu
Nepal
Phone: +977-9741283608
Email: kathmandu@jaypeebrothers.com

Website: www.jaypeebrothers.com
Website: www.jaypeedigital.com

© 2018, Jaypee Brothers Medical Publishers

The views and opinions expressed in this book are solely those of the original contributor(s)/author(s) and do not necessarily represent those of editor(s) of the book.

All rights reserved. No part of this publication and Interactive DVD-ROM may be reproduced, stored or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission in writing of the publishers.

All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book.

Medical knowledge and practice change constantly. This book is designed to provide accurate, authoritative information about the subject matter in question. However, readers are advised to check the most current information available on procedures included and check information from the manufacturer of each product to be administered, to verify the recommended dose, formula, method and duration of administration, adverse effects and contraindications. It is the responsibility of the practitioner to take all appropriate safety precautions. Neither the publisher nor the author(s)/editor(s) assume any liability for any injury and/or damage to persons or property arising from or related to use of material in this book.

This book is sold on the understanding that the publisher is not engaged in providing professional medical services. If such advice or services are required, the services of a competent medical professional should be sought.

Every effort has been made where necessary to contact holders of copyright to obtain permission to reproduce copyright material. If any have been inadvertently overlooked, the publisher will be pleased to make the necessary arrangements at the first opportunity. The **CD/DVD-ROM** (if any) provided in the sealed envelope with this book is complimentary and free of cost. **Not meant for sale.**

Inquiries for bulk sales may be solicited at: jaypee@jaypeebrothers.com

RSSDI Yearbook of Diabetes 2017

First Edition: **2017**

ISBN: 978-93-5270-284-8

Printed at

Contributors

EDITOR-IN-CHIEF

Sujoy Ghosh DM FRCP (Lond, Glasg, Edin) FACE
Associate Professor
Department of Endocrinology
Institute of Post Graduate Medical Education and Research
Kolkata, West Bengal, India

SECTION AUTHORS

Sanjay Agarwal MD
Director
Aegle Clinic - Diabetes Care
Pune, Maharashtra, India

SR Aravind DNB
Director
Diacon Hospital
Bangalore, Karnataka, India

Sarita Bajaj MD DM FRCP
Director, Professor and Head
Department of Medicine
Moti Lal Nehru Medical College
Allahabad, Uttar Pradesh, India

Rana Bhattacharjee MD MRCP DM FICP
Faculty, Department of Endocrinology and Metabolism
IPGMER and SSKM Hospital
Kolkata, West Bengal, India

Rajeev Chawla MD FRSSDI FRCP FACE
Senior Consultant and Director
North Delhi Diabetes Centre
New Delhi, India

Partha P Chakraborty MD DM DNB
Assistant Professor
Department of Medicine
Midnapore Medical College and Hospital
Midnapore, West Bengal, India

Deep Dutta MBBS MD DM DNB MNAMS
Consultant and Head
Department of Endocrinology, Diabetology, and Metabolic Disorders, Venkateshwar Hospitals
New Delhi, India

Amritava Ghosh MD DM
Consultant
Department of Endocrinology
Narayana Multispecialty Hospital, Whitefield
Bengaluru, Karnataka, India

Soumik Goswami MD DM
RMO Cum Clinical Tutor
Department of Endocrinology
Nil Ratan Sircar Medical College and Hospital
Kolkata, West Bengal, India

Sunil Gupta MD FRCP (Edin, Glasg) FACP FICP FIAMS FIACM
Managing Director
Sunil's Diabetes Care n' Research Centre Pvt. Ltd.
Nagpur, Maharashtra, India

Jayaprakashsai Jana MD Dip. Diabetology FRSSDI
Consultant Diabetologist
Apollo Sugar Clinics
Hyderabad, Telangana, India

Sanjay Kalra DM
Consultant
Department of Endocrinology
Bharti Hospital
Karnal, Haryana, India

Vasanth Kumar MD
Senior Consultant
Apollo Hospitals
Hyderabad, Telangana, India

Indira Maisnam MD DM
Consultant
Department of Endocrinology
R. G. Kar Medical College
Kolkata, West Bengal, India

Anuj Maheshwari MD FICP FIACM FACP FACE FRCP
Professor and Head
Department of General Medicine
Babu Banarasi Das University
Lucknow, Uttar Pradesh, India

Brij M Makkar MD FRCP FACE
Director, Dr Makkar's Diabetes and Obesity Centre
New Delhi, India

Anand Moses MD FRCP
Professor
Department of Diabetology
Madras Medical College
Chennai, Tamil Nadu, India

Pradip Mukhopadhyay MD DM
Associate Professor
Department of Endocrinology
IPGMER and SSKM Hospital
Kolkata, West Bengal, India

Jayanta Panda MD FICP FACP FIMAMS FRSSDI
Associate Professor
Shri Ramachandra Bhanj Medical College
Cuttack, Odisha, India

Kaushik Pandit MD DM DNB
Consultant, Department of Endocrinology, Belle Vue Clinic
Kolkata, West Bengal, India

Vijay Panikar MD DNB FCPS
Consultant
Department of Endocrinology and Diabetes, Lilavati Hospital
Mumbai, Maharashtra, India

PV Rao MD PhD FRCP FACE
Former Senior Professor and Head
Department of Endocrinology and Metabolism
Nizam's Institute of Medical Sciences
Hyderabad, Andra Pradesh, India

Sayantan Ray MD DM
Consultant
Department of Endocrinology
Mission of Mercy Hospital and Research Centre
Kolkata, West Bengal, India

Ajitesh Roy MD DM
Honorary Assistant Professor
Department of Endocrinology
Vivekananda Institute of Medical Science and Ramakrishna Mission Seva Pratishthan
Kolkata, West Bengal, India

Banshi D Saboo MD PhD
Diabetologist
Department of Endocrinology
DIACARE
Ahmedabad, Gujarat, India

Rakesh Sahay MD DM FACE FICP FRSSDI
Professor and Head
Department of Endocrinology
Osmania General Hospital
Hyderabad, Telangana, India

Chitra Selvan DM MRCP
Assistant Professor
Department of Endocrinology
M S Ramaiah Medical College
Bengaluru, Karnataka, India

KR Narasimha Setty MD FRSSDI
Founder Director
Karnataka Institute of Diabetology
Bengaluru, Karnataka, India

Anirban Sinha MD DM FACE
Assistant Professor
Department of Endocrinology
Medical College Kolkata
Kolkata, West Bengal, India

Vijay Viswanathan MD PhD FICP FRCP FRCP
Head and Chief
Department of Diabetes
M V Hospital for Diabetes
Chennai, Tamil Nadu, India

EDITORIAL ASSISTANTS

Anjan Roy MSc
Senior Regional Medical Advisor
Sanofi India Limited
Kolkata, West Bengal, India

Kingshuk Bhattacharjee PhD MBA BPharma
Assistant Manager Medical Services, Biocon Limited
Bengaluru, Karnataka, India

Ranjini Sen MD
Senior Regional Medical Advisor
AstraZeneca Pharma India Ltd.
Kolkata, West Bengal, India

Message from the RSSDI President

The RSSDI Yearbook of Diabetes 2017 brings you the abstracts of the articles that reported 2 years recent and breakthrough developments in diabetes, carefully selected from many journals worldwide. Expert commentaries evaluate the clinical importance of each article.

This allows the reader to quickly identify and understand topics of interest which translates into practical application. The goals of the book are to be current, to be compact, to make the information accessible, and to be understandable by students of medicine of all ages.

The book is divided into 12 sections arranging closely related subjects into clusters. The sections span the spectrum of diabetes from basic science to future directions.

Together we salute and thank the Editor-in-Chief Dr Sujoy Ghosh for his expertise in the shaping and collation and for showing extraordinary commitment to maintaining the excellent standard. We are especially grateful to the editorial team comprising Dr Soumik Goswami, Dr Amritava Ghosh, Dr Sanjay Kalra, Dr Indira Maisnam, Dr Anuj Maheshwari, Dr Rana Bhattacharjee, Dr Sayantan Ray, Dr Rakesh Sahay, Dr Ajitesh Roy, Dr Rajeev Chawla, Dr Partha P Chakraborty, Dr Sanjay Agarwal, Dr Anirban Sinha, Dr Deep Dutta, Dr Kaushik Pandit, Dr Pradip Mukhopadhyay, and Dr Chitra Selvan who have provided endless support. We would also like to thank the editorial assistants Dr Anjan Roy, Mr Kingshuk Bhattacharjee, and Dr Ranjini Sen who have been instrumental in compiling this extensive work.

We all take immense pride in producing an outstanding book and hope that the reader will agree that the excellence of the writing and scholarly rigor displayed by the authors make a strong argument for its endurance as an outstanding resource for education and teaching in diabetes.

Sarita Bajaj MD DM FRCP
President, RSSDI
Director, Professor and Head
Department of Medicine
Moti Lal Nehru Medical College
Allahabad, Uttar Pradesh, India

Message from the RSSDI Secretary

It is indeed a matter of great pride that Research Society for the Study of Diabetes in India (RSSDI) is publishing "RSSDI Yearbook of Diabetes 2017" which will be released at the 45th RSSDI Annual Conference of the RSSDI at Bhubaneshwar on 3–5 November 2017. One of the key endeavors of RSSDI has been to promote research and education in the field of diabetes in India. A "yearbook," a compilation of assorted research papers in diabetes and allied subjects published during the preceding one year will be an important source of all the recent developments in understanding of diabetes and provide a great knowledge tool for physicians, postgraduates, and researchers. Hopefully this will ultimately translate into motivation for more research in diabetes and better patient care. Personally, I am more than pleased to be part of this great educational venture. My compliments to Dr Sujoy Ghosh and the editorial team and my best wishes for the RSSDI Yearbook of Diabetes 2017.

Brij M Makkar MD FRCP FACE
Honorary Secretary, RSSDI
Director
Dr Makkar's Diabetes and Obesity Centre
New Delhi, India

Preface

Incidentally, yearbooks in various specialties are available for almost all specialties and sub-/super-specialties of medical sciences. However, a yearbook of diabetes is not available. Given the fact that 44,337 articles related to diabetes have been published on PubMed in 2016 itself, it is not surprising that no one has embarked upon taking the herculean task of writing a yearbook on diabetes.

Being a teacher, I have been often asked by students which studies to read and how to interpret them. Clinicians, both primary care and specialists often attend conferences and clinical meetings with the expectation to update their understanding of diabetology. Clinical service delivery makes it difficult for most to keep abreast with all the new studies published. Others have at various points expressed their inability to interpret clinical studies and at other times physicians have been swayed by deliberate or inadvertent biased interpretation of clinical studies both by pharmaceutical companies as well as "key opinion leaders."

Hence, it is imperative that a yearbook containing the most important publications are summarized in an easy to read format for the physician be published. The Research Society for the Study of Diabetes in India (RSSDI) is one of the biggest organizations in the field of diabetology worldwide and is, therefore, the apt organization to take up the responsibility.

But why did I agree upon taking this challenge? As I took up this challenge with our editorial team/authors, I was reminded of the words of Authur Conan Doyle (The Hound of the Baskervilles), "the boldest, or it may be the most drunken, rode forward."

We decided to screen all diabetes related (major publications, from major journals) published between 1st July 2016 and 30th June 2017. We screened almost 30,000 original research articles and then divided up the selected articles into 12 subsections and wrote up a critical appraisal of all the selected ones. The unstructured write-ups tried to provide background information on what was already known about the issue prior to the particular publication, what the study added in terms of medical knowledge, and what the take home for the physician is, as well as highlights the possible strengths and limitations of the study and the scope of future research.

I was fortunate to be working with an outstanding team of doctors, including a dynamic editorial team consisting a mix of a biostatistician and doctors (including specialist in pharmacology), physicians, diabetologists, and endocrinologists. I would like to put on record my thanks to my editorial assistance team of Dr Anjan Roy, Mr Kingshuk Bhattacharjee, and Dr Ranjini Sen. The entire writing team of doctors for the book have done a splendid job, that too at such short notice.

I am highly indebted to all the members of the Executive Committee of RSSDI, especially Dr Sarita Bajaj, Dr Brij Mohan Makkar, Dr Rajeev Chawla, and Dr SR Aravind. We also acknowledge the kind support and help that we have received from the American Diabetes Association and

several other international publishing houses and national journals/associations in providing us permission to reproduce abstracts of articles published in their journals.

The entire process of completion of this book has been a roller-coaster journey. Particularly because of the copyright issues and other technical matters. The book would never have seen the light of day without the persistence, help, support, and guidance that I received from Mr Sabyasachi Hazra of Jaypee Brothers Medical Publishers (P) Ltd.

Finally, I would like to thank all my colleagues at work and my family who have been a constant source of encouragement and support.

I dedicate this book to all those involved in the management of patients with diabetes and hope this helps in improvement of patient care and outcome.

Sujoy Ghosh

Contents

Section 1: Basic Science

Section Authors: Soumik Goswami, Brij M Makkar, PV Rao, Vijay Viswanathan

1. Association of 1,5-Anhydroglucitol, a Biomarker of Glucose Peaks, with Subclinical Cardiovascular Disease 1
2. Changes in Metabolic Hormones after Bariatric Surgery and Their Predictive Impact on Weight Loss 2
3. Fall in C-Peptide during First 4 Years from Diagnosis of Type 1 Diabetes Mellitus: Variable Relation to Age, HbA1c, and Insulin Dose 4
4. Systems Biology-derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes Mellitus 5
5. Proinflammatory Cytokines Predict the Incidence and Progression of Distal Sensorimotor Polyneuropathy: KORA F4/FF4 Study 7
6. Association between Changes in Estradiol and Follicle-stimulating Hormone Levels during the Menopausal Transition and Risk of Diabetes Mellitus 8
7. Effect of Serotonin Transporter 5-HTTLPR Polymorphism on Gastrointestinal Intolerance to Metformin: A GoDARTS Study 10
8. Duodenal Mucosa of Patients with Type 1 Diabetes Shows Distinctive Inflammatory Profile and Microbiota 12
9. Urinary Exosomal MicroRNA Panel Unravels Novel Biomarkers for Diagnosis of Type 2 Diabetic Kidney Disease 13
10. Microarray Analysis of Long Noncoding RNA Expression Patterns in Diabetic Nephropathy 14
11. Serum Trypsinogen Levels in Type 1 Diabetes 16
12. Evidence of β-cell Dedifferentiation in Human Type 2 Diabetes 17
13. Reversion of β-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study 19
14. High Serum Oxytocin is Associated with Metabolic Syndrome in Older Men – the MINOS Study 20

Section 2: Epidemiology

Section Authors: Amritava Ghosh, Sanjay Kalra, Anand Moses, Vijay Panikar

1. Mortality in Type 1 Diabetes in the DCCT/EDIC Versus the General Population 23
2. Frequency of Evidence-based Screening for Retinopathy in Type 1 Diabetes 24

3. Cardiovascular Autonomic Neuropathy and Cardiovascular Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study 27
4. Hemoglobin A1c and Mortality in Older Adults with and without Diabetes: Results from the National Health and Nutrition Examination Surveys (1988–2011) 29
5. Early Glycemic Control and Magnitude of HbA1c Reduction Predict Cardiovascular Events and Mortality: Population-Based Cohort Study of 24,752 Metformin Initiators 32
6. Association between Inpatient Sleep Loss and Hyperglycemia of Hospitalization 34
7. Insulin Resistance Predicts Cognitive Decline: An 11-Year Follow-up of a Nationally Representative Adult Population Sample 36
8. Strengths, Risk Factors, and Resilient Outcomes in Adolescents with Type 1 Diabetes: Results from Diabetes MILES Youth–Australia 38
9. The Association between Educational Resource Utilization and Knowledge/Self-management among Patients with Type 2 Diabetes in Pune, India 40
10. Representation of People of South Asian Origin in Cardiovascular Outcome Trials of Glucose-lowering Therapies in Type 2 Diabetes 41
11. Is there Evidence of Potential Overtreatment of Glycaemia in Elderly People with Type 2 Diabetes? Data from the GUIDANCE Study 43
12. Hormonal Contraception and Risk of Thromboembolism in Women with Diabetes 44
13. Association between Serum 25(OH)D3 and Cardiovascular Morbidity and Mortality in People with Type 2 Diabetes: A Community-based Cohort Study 46
14. Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the UK Pediatric Diabetes Population with Monogenic Diabetes 47
15. Prolonged Sitting may Increase Diabetes Risk in Physically Inactive Individuals: An 11 Years Follow-up of the HUNT Study, Norway 49
16. Life Expectancy and Cause-specific Mortality in Type 2 Diabetes: A Population-based Cohort Study Quantifying Relationships in Ethnic Subgroups 52
17. The Association between Sclerostin and Incident Type 2 Diabetes Risk: A Cohort Study 53

Section 3: Type 1 Diabetes Mellitus

Section Authors: Indira Maisnam, Anuj Maheshwari, Sunil Gupta, KR Narasimha Setty

1. Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes 56
2. Association of Glycemic Variability in Type 1 Diabetes with Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial 58
3. Coprogression of Cardiovascular Risk Factors in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study 60
4. Diurnal Differences in Risk of Cardiac Arrhythmias During Spontaneous Hypoglycemia in Young People with Type 1 Diabetes 63
5. Impact of Sleep Behavior on Glycemic Control in Type 1 Diabetes: The Role of Social Jetlag 66

6. Circulating Modified Metabolites and a Risk of ESRD in Patients with Type 1 Diabetes and Chronic Kidney Disease 68
7. Increased Hormone-negative Endocrine Cells in the Pancreas in Type 1 Diabetes 70
8. Late-onset Islet Autoimmunity in Childhood: The Diabetes Autoimmunity Study in the Young (DAISY) 73
9. Infant Feeding and Risk of Type 1 Diabetes in Two Large Scandinavian Birth Cohorts 75
10. The Impact of Continuous Glucose Monitoring on Markers of Quality of Life in Adults with Type 1 Diabetes: Further Findings From the DIAMOND Randomized Clinical Trial 77
11. Fast-acting Insulin Aspart Improves Glycemic Control in Basal-bolus Treatment for Type 1 Diabetes: Results of a 26-week Multicenter, Active-controlled, Treat-to-target, Randomized, Parallel-Group Trial (Onset 1) 79

Section 4: Gestational Diabetes Mellitus

Section Authors: Rana Bhattacharjee, Sunil Gupta, Sanjay Kalra, Vasanth Kumar

1A. A Longitudinal Study of Iron Status During Pregnancy and the Risk of Gestational Diabetes: Findings From a Prospective, Multiracial Cohort 82
1B. Systematic Review or Meta-analysis: High Maternal Iron Status, Dietary Iron Intake and Iron Supplement use in Pregnancy and Risk of Gestational Diabetes Mellitus: A Prospective Study and Systematic Review 82
2. Translating HbA1c Measurements into Estimated Average Glucose Values in Pregnant Women with Diabetes 84
3. Conversion of Gestational Diabetes Mellitus to Future Type 2 Diabetes Mellitus and the Predictive Value of HbA1c in an Indian Cohort 85
4. Plasma Fatty Acid-binding Protein 4 (FABP4) as a Novel Biomarker to Predict Gestational Diabetes Mellitus 86
5. Maternal BMI and Glycemia Impact the Fetal Metabolome 87
6. In Utero Exposure to Maternal Hyperglycemia Increases Childhood Cardiometabolic Risk in Offspring 88
7. Glyburide versus Metformin and Their Combination for the Treatment of Gestational Diabetes Mellitus: A Randomized Controlled Study 89
8. A Predictive Metabolic Signature for the Transition from Gestational Diabetes to Type 2 Diabetes 91
9. Maternal and Neonatal Morbidity for Women Who Would be Added to the Diagnosis of GDM Using IADPSG Criteria: A Secondary Analysis of the Hyperglycemia and Adverse Pregnancy Outcome Study 92
10. Targeted Metabolomics Demonstrates Distinct and Overlapping Maternal Metabolites Associated with BMI, Glucose, and Insulin Sensitivity During Pregnancy Across Four Ancestry Groups 93
11. Insulin Therapy in Women with Pregestational Type 2 Diabetes and Its Relevance to Maternal and Neonatal Complications 94

Section 5: Comorbidities

Section Authors: Ajitesh Roy, Rakesh Sahay, Brij M Makkar, Rajeev Chawla

1. Effect of Sacubitril/Valsartan versus Enalapril on Glycaemic Control in Patients with Heart Failure and Diabetes: A Post-hoc Analysis from the PARADIGM-HF Trial 96
2. Association between High and Very High Albuminuria and Nighttime Blood Pressure: Influence of Diabetes and Chronic Kidney Disease 98
3. Impact of Renal Function on the Effects of LDL Cholesterol Lowering with Statin-based Regimens: A Meta-analysis of Individual Participant Data from 28 Randomised Trials 100
4. Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study 102
5. Type 2 Diabetes and Osteoarthritis: A Systematic Review and Meta-analysis 104
6. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes 105
7. Urinary Haptoglobin Predicts Rapid Renal Function Decline in Asians with Type 2 Diabetes and Early Kidney Disease 107
8. Management of Atherosclerotic Cardiovascular Disease Risk Factors in the Older Adult Patient with Diabetes 109
9. Association between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients with Chronic Heart Failure: Results from the ESC-HFA Heart Failure Long-Term Registry 112
10. Cognitive Dysfunction in Older Adults with Diabetes: What a Clinician Needs to Know 114
11. Prevalence of Co-morbidities in Type 2 Diabetes Mellitus Patients, the Awareness Level and the Impact of Pharmacist's Patient Education Program 116

Section 6: Complications

Section Authors: Sayantan Ray, Rajeev Chawla, Anand Moses, SR Aravind

1. Cognitive Dysfunction in Older Adults with Diabetes: What a Clinician Needs to Know 118
2. Insulin Resistance and Cognitive Performance in Type 2 Diabetes Mellitus—The Maastricht Study 120
3. Diabetic Nephropathy: New Insights into Established Therapeutic Paradigms and Novel Molecular Targets 122
4. Diabetic Neuropathy: A Position Statement by the American Diabetes Association 125
5. Diabetic Retinopathy: A Position Statement by the American Diabetes Association 127
6. Antagonism of Vasopressin V2 Receptor Improves Albuminuria at the Early Stage of Diabetic Nephropathy in a Mouse Model of Type 2 Diabetes 130
7. Diabetic Striatopathy and Ketoacidosis: Report of Two Cases and Review of Literature 132
8. Diabetic Macular Oedema: Pathophysiology, Management Challenges and Treatment Resistance 133
9. Diabetic Ketoacidosis without Diabetes 136

10. Systematic Review or Meta-analysis Aspirin for Primary Prevention of Cardiovascular and All-cause Mortality Events in Diabetes: Updated Meta-analysis of Randomized Controlled Trials 138
11. Declining Trends of Cardiovascular-renal Complications and Mortality in Type 2 Diabetes Mellitus: The Hong Kong Diabetes Database 140
12. Management of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Call to Action 142
13. Genetically Driven Hyperglycemia Increases Risk of Coronary Artery Disease Separately From Type 2 Diabetes 145
14. Association between HbA1c Variability and Risk of Microvascular Complications in Adolescents With Type 1 Diabetes 147
15. Comparative Effectiveness of Diabetic Oral Medications Among HIV-Infected and HIV-Uninfected Veterans 148
16. Diagnosis of Endocrine Disease: Prevalence of Hypercortisolism in Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-analysis 150
17. Lack of Independent Association between Fatty Pancreas and Incidence of Type 2 Diabetes Mellitus: 5-Year Japanese Cohort Study 153

Section 7: Drugs and Therapeutics

Section Authors: Partha P Chakraborty, Sanjay Agarwal, SR Aravind, Vijay Viswanathan

1. Metformin Use in Prediabetes Among U.S. Adults, 2005–2012 155
2. Metformin, Lifestyle Intervention, and Cognition in the Diabetes Prevention Program Outcomes Study 156
3. Metformin Use and Risk of Lactic Acidosis in People with Diabetes with and without Renal Impairment: A Cohort Study in Denmark and the UK 158
4. Pioglitazone Use and Risk of Bladder Cancer in Patients with Type 2 Diabetes: Retrospective Cohort Study Using Datasets from Four European Countries 159
5. Pioglitazone Prevents Diabetes in Insulin-resistant Patients with Cerebrovascular Disease 160
6. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis 162
7. Effects of Pioglitazone on the Incidence of Dementia in Patients with Diabetes 163
8. Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-regression Analysis of the Observational Studies 166
9. Addition of Sulphonylurea to Metformin Does not Relevantly Change Body Weight: A Prospective Observational Cohort Study (ZODIAC-39) 168
10. Combined Analysis of Three Large Interventional Trials with Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients with Type 2 Diabetes 169
11. Efficacy, Safety and Albuminuria-reducing Effect of Gemigliptin in Korean Type 2 Diabetes Patients with Moderate to Severe Renal Impairment: A 12-week, Double-blind Randomized Study (the GUARD Study) 171
12. Linagliptin and Its Effects on Hyperglycaemia and Albuminuria in Patients with Type 2 Diabetes and Renal Dysfunction: The Randomized MARLINA-T2D Trial 172

13. Effect of Linagliptin on Pulse Wave Velocity in Early Type 2 Diabetes: A Randomized, Double-blind, Controlled 26-week Trial (RELEASE) 174
14. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial 175
15. Assessment of Saxagliptin Efficacy: Meta-analysis of 14 Phase 2 and 3 Clinical Trials 177
16. Efficacy of Sitagliptin for the Hospital Management of General Medicine and Surgery Patients with Type 2 Diabetes (Sita-Hospital): A Multicentre, Prospective, Open-label, Non-inferiority Randomised Trial 178
17. Teneligliptin Real-world Efficacy Assessment of Type 2 Diabetes Mellitus Patients in India (TREAT-INDIA Study) 180
18. Efficacy and Safety of Teneligliptin in Addition to Insulin Therapy in Type 2 Diabetes Mellitus Patients on Hemodialysis Evaluated by Continuous Glucose Monitoring 182
19. Cardiovascular Safety of Vildagliptin in Patients with Type 2 Diabetes: A European Multi-database, Non-interventional Post-authorization Safety Study 184
20. Long-term Efficacy and Safety of Vildagliptin Add-on Therapy in Type 2 Diabetes Mellitus with Insulin Treatment 185
21. Incretin Based Treatments and Mortality in Patients with Type 2 Diabetes: Systematic Review and Meta-analysis 186
22. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes 187
23. Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes Based on History of Cardiovascular Disease or Cardiovascular Risk Factors: A Post Hoc Analysis of Pooled Data 189
24. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-glucose Cotransporter-2 Inhibitors versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-glucose Cotransporter-2 Inhibitors) 191
25. Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes 192
26. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials 193
27. Empagliflozin and Cerebrovascular Events in Patients with Type 2 Diabetes Mellitus at High Cardiovascular Risk 195
28. Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Diabetic Ketoacidosis among Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials 196
29. Placebo-controlled, Randomized Trial of the Addition of Once-weekly Glucagon-like Peptide-1 Receptor Agonist Dulaglutide to Titrated Daily Insulin Glargine in Patients with Type 2 Diabetes (AWARD-9) 197
30. Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-label Extension of the DURATION-1 Study 199
31. Exenatide Once Weekly plus Dapagliflozin Once Daily versus Exenatide or Dapagliflozin Alone in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy (DURATION-8): A 28 Week, Multicentre, Double-blind, Phase 3, Randomised Controlled Trial 200
32. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes 202

33. Amylase, Lipase, and Acute Pancreatitis in People with Type 2 Diabetes Treated with Liraglutide: Results from the LEADER Randomized Trial 204
34. Diurnal Glucose Exposure Profiles of Patients Treated with Lixisenatide before Breakfast or the Main Meal of the Day: An Analysis Using Continuous Glucose Monitoring 206
35. Efficacy and Safety of Lixisenatide in Patients with Type 2 Diabetes and Renal Impairment 207
36. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes 209
37. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes 211
38. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients with Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial 213
39. Hypoglycemia in Diabetes: Does Insulin Type Matter? 214
40. Faster Aspart Versus Insulin Aspart As Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The Onset 2 Trial 216
41. The Durability of Basal Insulin Affects Day-to-day Glycemic Variability Assessed by Continuous Glucose Monitoring in Type 2 Diabetes Patients: A Randomized Crossover Trial 217
42. Clinical Experience with U-500 Regular Insulin by Multiple Daily Injections and Continuous Subcutaneous Insulin Infusion 218
43. Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials 220
44. Treatment Intensification with an Insulin Degludec (IDeg)/Insulin Aspart (IAsp) Co-Formulation Twice Daily Compared with Basal IDeg and Prandial IAsp in Type 2 Diabetes: A Randomized, Controlled Phase III Trial 221
45. Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program 222
46. iGlarLixi, a Titratable Once-daily Fixed-ratio Combination of Basal Insulin and Lixisenatide for Intensifying Type 2 Diabetes Management for Patients Inadequately Controlled on Basal Insulin with or without Oral Agents 224
47. Insulin and Glucagon-like Peptide1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials 225
48. Effects of Intensive Glucose Control on Microvascular Outcomes in Patients with Type 2 Diabetes: A Meta-analysis of Individual Participant Data from Randomised Controlled Trials 227
49. Years of Life Gained by Multifactorial Intervention in Patients with Type 2 Diabetes Mellitus and Microalbuminuria: 21 Years Follow-up on the Steno-2 Randomised Trial 229
50. Resveratrol as Add-on Therapy in Subjects with Well-controlled Type 2 Diabetes: A Randomized Controlled Trial 230
51. Effects of Vitamin D Supplementation on Insulin Sensitivity and Insulin Secretion in Subjects with Type 2 Diabetes and Vitamin D Deficiency: A Randomized Controlled Trial 231

52. Probiotics for the Management of Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis 233
53. Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis from the First-in-human Proof-of-concept Study 234
54. Critical Role for GLP-1 in Symptomaticpost-bariatric Hypoglycaemia 236
55. Long-term Outcomes of Bariatric Surgery in Adolescents with Severe Obesity (FABS-5+): A Prospective Follow-up Analysis 237
56. Bariatric Surgery versus Intensive Medical Therapy for Diabetes – 5-Year Outcomes 239

Section 8: Paramedical Care in Diabetes

Section Authors: Anirban Sinha, Vasanth Kumar, Banshi D Saboo, Sanjay Agarwal

1. Educational and Psychological Aspects: Correlates of Psychological Care Strategies for People with Diabetes in the Second Diabetes Attitudes, Wishes and Needs (DAWN2™) Study 241
2. Educational and Psychological Aspects: Correlates of Psychological Outcomes Among Family Members of People with Diabetes in the Second Diabetes Attitudes, Wishes and Needs (DAWN2™) Study 243
3. Educational and Psychological Aspects: Correlates of Psychological Outcomes in People with Diabetes: Results from the Second Diabetes Attitudes, Wishes and Needs (DAWN2™) Study 244
4. Diabetes Education of Patients and Their Entourage: Out-of-hospital National Study (EDUCATED 2) 246
5. Psychosocial Care for People with Diabetes: A Position Statement of the American Diabetes Association 247
6. Effectiveness of Cognitive–behavioral Therapy on Glycemic Control and Psychological Outcomes in Adults with Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials 251
7. Cost-effectiveness of the 2014 U.S. Preventive Services Task Force (USPSTF) Recommendations for Intensive Behavioral Counselling Interventions for Adults with Cardiovascular Risk Factors 253
8. Systematic Review on the Cost-effectiveness of Self-management Education Programme for Type 2 Diabetes Mellitus 255
9. Fracture Liaison Services: Multidisciplinary Approaches to Secondary Fracture Prevention 257

Section 9: Indian Research

Section Authors: Deep Dutta, Sarita Bajaj, Anuj Maheshwari, Jayanta Panda

1. Coexistence of Celiac Disease and Type 1 Diabetes Mellitus in Children 260
2. Comparative Study of Clinical Features of Patients with Celiac Disease & Those with Concurrent Celiac Disease & Type 1 Diabetes Mellitus 261
3. Prevalence of Diabetes and Prediabetes in 15 States of India: Results from the ICMR-INDIAB Population-based Cross-sectional Study 262
4. Effects of Thyroid Status on Glycated Hemoglobin 264

5. A Study to Evaluate the Prevalence of Hypogonadism in Indian Males with Type-2 Diabetes Mellitus 265
6. Neck Height Ratio is an Important Predictor of Metabolic Syndrome Among Asian Indians 266
7. Postpartum Development of Type 1 Diabetes in Asian Indian Women with Gestational Diabetes 267
8. Evaluation of Accuracy of Ambulatory Glucose Profile in an Outpatient Setting in Children with Type 1 Diabetes 268
9. Impact of Self-monitoring of Blood Glucose Log Reliability on Long-term Glycemic Outcomes in Children with Type 1 Diabetes 269
10. Gut Microbiota in Type 2 Diabetes Individuals and Correlation with Monocyte Chemo attractant Protein 1 and Interferon Gamma from Patients Attending a Tertiary Care Centre in Chennai, India 271
11. Serum Vitamin B12 Levels in Type 2 Diabetes Patients on Metformin Compared to those Never on Metformin: A Cross-sectional Study 272
12. Factors Associated with Mortality in Children with Diabetic Ketoacidosis (DKA) in South India 273
13. Prevalence of 25-hydroxy Vitamin D Deficiency Among Type 2 Diabetic Subjects of South India 274
14. Association of ***TCF7L2*** Gene Variant with T2DM, T1DM and Gestational Diabetes in the Population of Northeastern UP, India 275
15. Relationship of Glycemic Control Markers - 1,5 Anhydroglucitol, Fructosamine, and Glycated Hemoglobin Among Asian Indians with Different Degrees of Glucose Intolerance 276
16. A Study of Asymptomatic Bacteriuria in North Indian Type 2 Diabetic Patients 277
17. Prevalence and Predictors of Depression and Anxiety in Patients of Diabetes Mellitus in a Tertiary Care Center 279
18. Serum Adiponectin Levels in Gestational Diabetes Mellitus 280
19. Derivation & Validation of Glycosylated Haemoglobin (HbA1c) Cut-off Value as a Diagnostic Test for Type 2 Diabetes in South Indian Population 281
20. Prevalence and Risk Factors of Pre-diabetes and Diabetes Among Patients with Active TB Disease Attending Three RNTCP Centres in Odisha 282
21. The Efficacy of Topical Phenytoin in the Healing of Diabetic Foot Ulcers: A Randomized Double-blinded Trial 284
22. Effect of Glycaemic Control on the Diurnal Blood Pressure Variation and Endogenous Secretory Receptor for Advanced Glycation End Product (esRAGE) Levels in Type 1 Diabetes Mellitus 285
23. Individuals with Diabetes are at a Higher Risk of Asthma in India: Evidence from the National Family Health Survey-3 287

Section 10: Newer Technologies

Section Authors: Kaushik Pandit, Rakesh Sahay, PV Rao, Jayaprakashsai Jana

1. Long-term Prediction of Cardiovascular Outcomes by Circulating $CD34^+$ and $CD34^+CD133^+$ Stem Cells in Patients with Type 2 Diabetes 288

2. Plasma Glycated CD59, a Novel Biomarker for Detection of Pregnancy-induced Glucose Intolerance 289
3. Proteomics for Prediction of Disease Progression and Response to Therapy in Diabetic Kidney Disease 290
4. The Gut Microbiome as a Target for Prevention and Treatment of Hyperglycaemia in Type 2 Diabetes: From Current Human Evidence to Future Possibilities 291
5. Type 2 Diabetes Remission Rates After Laparoscopic Gastric Bypass and Gastric Banding: Results of the Longitudinal Assessment of Bariatric Surgery Study 292
6. Randomized Trial of a Dual-hormone Artificial Pancreas with Dosing Adjustment During Exercise Compared with No Adjustment and Sensor-augmented Pump Therapy 294
7. Angiogenic Effects of Low-intensity Cathodal Direct Current on Ischemic Diabetic Foot Ulcers: A Randomized Controlled Trial 295
8. "Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor-augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients 296
9. A Clinical Trial of the Accuracy and Treatment Experience of the Flash Glucose Monitor FreeStyle Libre in Adults with Type 1 Diabetes 297
10. Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting 298
11. Efficacy of the Telemedical Lifestyle Intervention Program TeLiPro in Advanced Stages of Type 2 Diabetes: A Randomized Controlled Trial 299
12. Do Mobile Phone Applications Improve Glycemic Control (HbA1c) in the Self-management of Diabetes? A Systematic Review, Meta-analysis, and GRADE of 14 Randomized Trials 300

Section 11: Newer Guidelines

Section Authors: Pradip Mukhopadhyay, Banshi D Saboo, Vijay Panikar, Jayanta Panda

1. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm—2017 Executive Summary 302
2. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease—Executive Summary 307
3. Management of Inpatient Hyperglycemia and Diabetes in Older Adults 311
4. Diabetes and Ramadan: Practical guidelines 314
5. Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes 318
6. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations 319
7. Non-alcoholic fatty liver disease (NAFLD): Summary of NICE Guidance 322

8. Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association 324
9. Standards of Medical Care in Diabetes- 2017 (American Diabetes Association): Twenty Points One Should Know 328

Section 12: Future Directions

Section Authors: Chitra Selvan, Sarita Bajaj, KR Narasimha Setty, Jayaprakashsai Jana

1. The Role of Obestatin in Roux-en-Y Gastric Bypass Surgery in the Obese, Type 2 Diabetes Zucker Rat 332
2. Efficacy and Safety of Metreleptin Therapy in Patients With Type 1 Diabetes: A Pilot Study 333
3. Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes 334
4. The Effects of Atrasentan on Urinary Metabolites in Patients with Type 2 Diabetes and Nephropathy 336
5. Comparing the GFR Estimation Equations Using Both Creatinine and Cystitis C to Predict the Long-term Renal Outcome in Type 2 Diabetic Nephropathy Patients 337
6. Identification of Unique Antigenic Determinants in the Amino Terminus of IA-2 (ICA512) in Childhood and Adult Autoimmune Diabetes: New Biomarker Development 339
7. ANGPTL2 is Associated with an Increased Risk of Cardiovascular Events and Death in Diabetic Patients 340
8. Impact of Proton Pump Inhibitor Treatment on Pancreatic Beta-cell Area and Beta-cell Proliferation in Humans 341
9. Measuring the Stigma Surrounding Type 2 Diabetes: Development and Validation of the Type 2 Diabetes Stigma Assessment Scale (DSAS-2) 343
10. Bile Acid Sequestrants for Glycemic Control in Patients with Type 2 Diabetes: A Systematic Review with Meta-analysis of Randomized Controlled Trials 344
11. A Novel and Practical Screening Tool for the Detection of Silent Myocardial Infarction in Patients With Type 2 Diabetes 346
12. An Unbiased Lipidomics Approach Identifies Early Second Trimester Lipids Predictive of Maternal Glycemic Traits and Gestational Diabetes Mellitus 347
13. A Randomized Controlled Study of Finerenone versus Placebo in Japanese Patients with Type 2 Diabetes Mellitus and Diabetic Nephropathy 349

Index ***351***